Results 1 to 10 of about 32,388 (183)

Non-Adherence in Adult Male Patients with Community-Acquired Pneumonia: Relative Forgiveness of Amoxicillin versus Respiratory Fluoroquinolones [PDF]

Antibiotics, 2023
The consequences of non-adherence to treatment (NAT) on antimicrobial efficacy may depend on drug forgiveness—a property that should account for pharmacokinetics (PK) and pharmacodynamics (PD) as well as interindividual variability.
Nerea Carral, John C. Lukas, Oskar Estradé, Nerea Jauregizar, Héctor Morillas, Elena Suárez   +5 more
doaj   +4 more sources

Respiratory Fluoroquinolones Monotherapy vs. β-Lactams With or Without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis [PDF]

Frontiers in Pharmacology, 2019
Background: The choice of empirical antibiotic treatment for patients with community-acquired pneumonia (CAP) who are admitted to non-intensive care unit (ICU) hospital wards is complicated by the limited availability of evidence.
Sitong Liu, Xiang Tong, Yao Ma, Dongguang Wang, Jizhen Huang, Li Zhang, Man Wu, Lei Wang, Tao Liu, Hong Fan   +9 more
doaj   +4 more sources

Respiratory fluoroquinolones in outpatient clinical practice

Медицинский совет, 2015
Advancements in fluoroquinolones (FQ) resulted in the development of the so-called respiratory quinolones which are different from their predecessors in having a stronger clinically significant effect against gram-positive pathogens of relevant human ...
R. S. Kozlov, A. V. Golub
doaj   +2 more sources

(Fluoro)quinolone prescriptions for upper respiratory tract infections in the German outpatient sector: a health insurance claims analysis [PDF]

GMS Infectious Diseases
Background: Acute upper respiratory tract infections (URTIs) are frequent causes of medical treatment by general practitioners (GPs). In general, these are viral and self-limiting illnesses, but antibiotics are prescribed.
Arens, Birgit , L’hoest, Helmut, Wolf, Alissa, Hennig, Beata, Marschall, Ursula, Nachtigall, Irit   +5 more
doaj   +2 more sources

Immunomodulatory Effects of Fluoroquinolones in Community-Acquired Pneumonia-Associated Acute Respiratory Distress Syndrome [PDF]

Biomedicines
Community-acquired pneumonia is reported as one of the infectious diseases that leads to the development of acute respiratory distress syndrome. The innate immune system is the first line of defence against microbial invasion; however, its dysregulation ...
Resti Yudhawati, Nisrina Fitriyanti Wicaksono   +1 more
doaj   +2 more sources

Could Respiratory Fluoroquinolones, Levofloxacin and Moxifloxacin, Prove to be Beneficial as an Adjunct Treatment in COVID-19? [PDF]

Arch Med Res, 2020
Karampela I, Dalamaga M.
europepmc   +3 more sources

Analysis of Respiratory Fluoroquinolones and the Risk of Sudden Cardiac Death Among Patients Receiving Hemodialysis.

JAMA Cardiol, 2022
Assimon MM, Pun PH, Wang LC, Al-Khatib SM, Brookhart MA, Weber DJ, Winkelmayer WC, Flythe JE.   +7 more
europepmc   +3 more sources

PLACE OF RESPIRATORY FLUOROQUINOLONES IN THERAPY OF COMMUNITY ACQUIRED PNEUMONIA: FOCUS ON HIGH-DOSE LEVOFLOXACINE THERAPEUTIC REGIME

Медицинский совет, 2017
Community-acquired pneumonia is one of the most prevalent infectious diseases and there are numerous diagnostic and therapeutic mistakes in relation to it.
A. I. Sinopalnikov
doaj   +3 more sources

Algorithms for management of patients with severe A/H1N1 influenza: from diagnosis to respiratory support techniques. Guidelines

Consilium Medicum, 2023
In 2022, the incidence of swine (A/H1N1) influenza markedly increased. It causes acute lung injury similar to that caused by SARS-CoV-2. These practice guidelines focus on the management of patients with severe influenza: from the diagnostic algorithm to
Sergey N. Avdeev, Andrey A. Zaytsev, Konstantin V. Zhdanov, Mikhail B. Patsenko, Sergei A. Chernov, Valerii V. Stets, Nikolai P. Potekhin, Aleksander A. Sergoventsev, Denis V. Davydov, Evgeniy V. Kryukov, Vladimir A. Chernetsov   +10 more
doaj   +1 more source

Omadacycline in the treatment of community-acquired bacterial pneumonia in patients with comorbidities: a post-hoc analysis of the phase 3 OPTIC trial

Frontiers in Medicine, 2023
IntroductionThe 2019 American Thoracic Society/Infectious Disease Society of America guidelines recommend respiratory fluoroquinolones to treat community-acquired bacterial pneumonia (CABP) in adults with comorbidities.
George D. Rodriguez, George D. Rodriguez, Nathan Warren, Roman Yashayev, Surya Chitra, Maria Amodio-Groton, Kelly Wright   +6 more
doaj   +1 more source